Company · Private
Rejuvenate Bio
Gene therapy company developing AAV-delivered programmes, including FGF21-based constructs and partial-reprogramming approaches, against drivers of age-related disease.
Listing
Private
Ticker
—
Headquarters
San Diego, US
Founded
—
Technology
AAV gene therapy, partial reprogramming
Category
Longevity thesis
Delivering longevity-associated genes such as FGF21 directly could recapitulate systemic benefits that small molecules struggle to reach.
Programmes
- AAV gene therapy (FGF21)Preclinical
Age-related metabolic and cardiac disease
- Partial reprogramming programmePreclinical
Cellular rejuvenation
Reference information for research context only. It is not a rating, a valuation or investment advice. Published developments appear in the News archive.